SG biotech Tikva Allocell scores $8m Series A for cancer cell therapy

SG biotech Tikva Allocell scores $8m Series A for cancer cell therapy

Normal cells of human connective tissue in culture at a magnification of 500x. Photo by National Cancer Institute on Unsplash

Kantharos CapitalTikva Allocell

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter

You may also like

Read more from Singapore

Nikkei Logo
DealStreetAsia Logo
About Us
Team
Advertise
Contact
Careers
Blog
Privacy Policy
Terms & Conditions
© Copyright DEALSTREETASIA 2014-2026 All rights reserved.